Panel Discussion: Cracking the ‘Clean Target’ Challenge with Smarter Selection Strategies to Uncover Safe & Novel Targets

• What defines a ‘clean’ target in practice, and how should we balance prevalence, selectivity, and heterogeneity risks?
• How can emerging technologies like proteomics, spatial biology, and AI improve prediction of protein expression, localisation, and off-tumour toxicity risk?
• How can the field move beyond a limited pool of validated targets while generating robust preclinical data to de-risk novel target investment?

Speakers:

Duncan Howie

Director, Cell & Immunobiology

Enara Bio

Marcela Guzman Ayala

Senior Director & Head, In Vitro Pharmacology

Molecular Partners AG

Angus Sinclair

Chief Scientific Officer

LabGenius Therapeutics